NeuroTracker is CogniSens Athletics' first fully commercialized product for international markets. Over the past 3 years, it has been developed alongside other applications in collaboration with EPL teams, and over the past 2 years with the NHL teams. Several more patented technologies are nearing final development stages or undergoing in-field trials, detailed in this section.
NeuroMinder C3 is an upcoming system integrating three of these technologies (NeuroMinder, NeuroBalance and NeuroTracker) to provide comprehensive and objective assessments of neural status for managing concussions. A range of neural acuity baselines are used as references to measure the relative functional impact of mTBI on the athlete. Unlimited and accurate retests allow close monitoring of recovery and also provide checks on return of mTBI symptoms.
NeuroMinder C3 will offer the sports industry a unique solution to the detection and management of concussions.